Genmab — Marts 2012
-
i 2001
-
2011
-
og 60 mill i 2012
-
++++++++
-
Endelig
-
ja
-
Jep Efter luk
-
regnskabet bedre end guidet
-
AKA, hvad er Din vurdering mht. i morgen og fremtiden, jeg tolker det meget positiv
-
mine major takeaways
-
-
Er Dara tæt på???
-
De guider 90-100 mill på arzerra. Det er godt de guider!
-
på den korte bane kan daratumumab måske overraske med en upfront deal på et 3cifret million beløb
-
aka prøv af forklare det specielle med arezera overstige udgifts loftet i GSK aftalen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind